Peroxisome proliferator-activating receptors: A new way to treat melanoma?

Journal of Investigative Dermatology

Volumn 129, Issue 5, 2009, Pages 1061-1063

  Schadendorf, Dirk ^a  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTINEOPLASTIC AGENT; CIGLITAZONE; CYCLIN D1; GEMFIBROZIL; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ANTAGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; ROSIGLITAZONE; TROGLITAZONE;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER INHIBITION; CELL CYCLE ARREST; CONCENTRATION RESPONSE; DRUG EFFECT; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG TARGETING; HYPERGLYCEMIA; IN VITRO STUDY; IN VIVO STUDY; LETTER; MELANOMA; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL;

EID: 65249099572     PISSN: 0022202X     EISSN: 15231747     Source Type: Journal    
DOI: 10.1038/jid.2009.56     Document Type: Note

References (10)

1. Balakumar P, Rose M, Ganti SS, Krishan P, Singh M (2007) PPAR dual agonists: are they opening Pandora's box? Pharmacol Res 56:91-8
2. Balch CM, Buzaid AC, Soong SJ, Atkins MB, Cascinelli N, Coit DG et al. (2001) Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol 19:3635-48
3. Botton T, Puissant A, Bahadoran P, Annicotte J-S, Fajas L, Ortonne J-P et al. (2009) In vitro and In vivo antimelanoma effects of ciglitazone. J Invest Dermatol 129:1208-18
4. Boyd AS (2007)Thiazolidinediones in dermatology. Int J Dermatol 46:557-63
5. Chou FS, Wang PS, Kulp S, Pinzone JJ (2007) Effects of thiazolidinediones on differentiation, proliferation, and apoptosis. Mol Cancer Res 5:523-30
6. Grabacka M, Placha W, Urbanska K, Laidler P, Plonka PM, Reiss K (2008) PPAR gamma regulates MITF and beta catenin expression and promotes a differentiated phenotype. Pig Cell MeI Res 3:388-96
7. Hoek KS, Schlegel NC, Brafford P, Sucker A, Ugurel S, Kumar R et al. (2006) Metastatic potential of melanomas defined by specific gene expression profiles with no BRAF signature. Pig Cell Res 19:290-302
8. Liu Y, Meng Y, Liu H, Li J, Fu J, Liu Y et al. (2006) Growth inhibition and differentiation induced by peroxisome proliferator-activated receptor gamma ligand rosiglitazone in human melanoma cell line A375. Med Oncol 23:393-402
9. Sertznig P, Seifert M, Tilgen W, Reichrath J (2008) Peroxisome proliferator-activated receptors (PPARs) and the human skin: importance of PPARs in skin physiology and dermatologic diseases. Am j Clin Dermatol 9:15-31
10. Ugurel S, Houben R, Schrama D, Voigt H, Zapatka M, Schadendorf D et al. (2007) Microphthalmia-associated transcription factor gene amplification in metastatic melanoma is a prognostic marker for patient survival, but not a predictive marker for chemosensitivity and chemotherapy response. Clin Cancer Res 13:6344-50